CPHI China 2026 in Shanghai has officially come to a close, and what an incredible event it was for the global pharmaceutical community. CPHI China 2026 in Shanghai: A Successful Event for JYMed Peptide Over three dynamic days, thousands of pharma professionals,...
May 29 | 1. CSPC enters a $18.5 billion global licensing deal with AstraZeneca for peptide platform (including GLP-1 pipeline) Key Highlights: The deal comprises an upfront payment of $1.2 billion and a total potential value of up to $18.5 billion, setting a new...
We are pleased to announce that Dr. Beatriz G. de la Torre has joined JYMed Peptide as Principal Scientific Advisor.Dr. de la Torre has spent over three decades working at the intersection of peptide chemistry and biomedical research, with academic and research...
We are pleased to announce that Professor Fernando Albericio has joined JYMed Peptide as Chief Scientific Advisor.It is a privilege to welcome him to the team. Internationally recognized for his extensive contributions to peptide chemistry, including solid-phase...
Behind every peptide project, there are people making the work possible.From research and production to quality, operations, and customer support, Labor Day is the perfect time to recognize the teams whose dedication makes everything possible, every day.Happy Labor...
中文
